Endocrinology – Page 3

Age at Type 2 Diabetes Diagnosis and Mortality and Cardiovascular Risks, and Years of Life Lost in South Asians

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Ayodipupo

The Significant Reduction in Epicardial Adipose Tissue Thickness after Dapagliflozin Treatment Is Preserved and Even Increased after Four Years—The DAPAHEART Four- Year Follow-up Study

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Cassaandra

Dapagliflozin Alters TCA Cycle Activation during Insulin Withdrawal in T1D Patients

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Samantha

A Four-Week Treatment with Dapagliflozin Reduces Insulin- Stimulated Renal Glucose Uptake

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Shawn

Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP- 1/GIP Receptor Agonist (HDM1005)—A Phase I, Randomized, Double- Blind, Placebo- Controlled, Single and Multiple Dose- Escalation Study

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Junfang

Sustained Weight Reduction by Thresholds in Adults with Obesity and Prediabetes Treated with Tirzepatide over 176 Weeks (SURMOUNT-1)

This session was presented on Day 1, June 20th 2025 of the 85th American Diabetes Association Scientific Sessions, held in Chicago, IL by Dr. Jamy

Banting Medal Recipient Discusses Emerging Promise of Pharmacologic Treatment for Obesity And Diabetes

The approval of tirzepatide, the first dual incretin agonist, for the treatment of type 2 diabetes ushered in a “new era of metabolic medicine,” according

Researchers To Share Insights from Long-Term Comparison Of Surgical And Non- Surgical Interventions In Type 2 Diabetes

In type 2 diabetes, ARMMS-T2D is the largest and longest-running comparison of metabolic surgery versus medical and lifestyle intervention. In a symposium held on Monday,

Phase 3 Trial to Evaluate Efficacy and Safety of Gemigliptin and Dapagliflozin Dual Add-on Therapy to Metformin—SOLUTION 2 Study

This paper was presented on June 25 at the 83 American Diabetes Association ( ADA) Annual Scientific Session at San Diego by Drs Yong Soo

Real-World Impact of Oral Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE– Oral Semaglutide)

This paper was presented on June 25 at the 83 American Diabetes Association ( ADA) Annual Scientific Session at San Diego by Drs James Amamoo,